Additionally, CHAC1 downregulation results in increased levels of ferroptosis inhibitors such as GPX4 and SLC7A11, underscoring its pivotal role in controlling ferroptosis and its potential as a therapeutic target in bladder cancer (Yu et al., 2024). Here, CHAC1 is linked to urinary bladder carcinoma.